Skip to main content
← Science / Explained

SERIES: MYTHS READ AGAINST THE SCIENCE

FDA's 2026 review found no increased suicide risk across 91 trials

For suicidal ideation or behavior, FDA's January 2026 review did not find increased risk across 91 trials covering 107,910 patients and requested removal of that warning.

01

The Review

On January 13, 2026, the FDA announced the results of a comprehensive review of 91 studies of GLP-1 receptor agonist peptides covering 107,910 patients.

The review didn't find an increased risk of suicidal ideation or behavior. The agency asked manufacturers to remove the warning from the labels of Saxenda, Wegovy, and Zepbound.

02

The Backup Data

The review followed earlier reports that came in once the peptides were on the market, the same reports that had prompted the warning in the first place.

That finding is consistent with FDA's broader 2026 review.

03

What this means

References

  1. 01U.S. Food and Drug Administration Drug Safety Communication, January 13, 2026. SELECT trial: Lincoff et al. 2023, *New England Journal of Medicine* (PMID 37952131).Source line — see article body